Horizon Investments LLC Increases Stock Holdings in ICON Public Limited (NASDAQ:ICLR)

Horizon Investments LLC lifted its position in ICON Public Limited (NASDAQ:ICLR) by 534.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 653 shares of the medical research company’s stock after purchasing an additional 550 shares during the quarter. Horizon Investments LLC’s holdings in ICON Public were worth $137,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Natixis Advisors LLC lifted its position in ICON Public by 6.7% in the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock valued at $37,279,000 after buying an additional 11,177 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its position in shares of ICON Public by 40.6% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock worth $20,363,000 after purchasing an additional 28,050 shares in the last quarter. Foyston Gordon & Payne Inc acquired a new stake in shares of ICON Public during the third quarter worth about $11,672,000. Icon Wealth Advisors LLC lifted its position in shares of ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares in the last quarter. Finally, Entropy Technologies LP raised its holdings in ICON Public by 472.2% in the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock valued at $1,295,000 after acquiring an additional 5,095 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on ICLR. Truist Financial dropped their price target on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Citigroup lowered their target price on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. William Blair reissued an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research note on Wednesday, January 15th. Finally, JPMorgan Chase & Co. decreased their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ICON Public currently has a consensus rating of “Moderate Buy” and a consensus price target of $279.17.

ICON Public Price Performance

NASDAQ:ICLR opened at $183.96 on Friday. The firm has a market cap of $14.86 billion, a price-to-earnings ratio of 19.30, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. The company’s 50-day moving average is $193.43 and its two-hundred day moving average is $227.86. ICON Public Limited has a 12-month low of $174.93 and a 12-month high of $347.72.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. Research analysts expect that ICON Public Limited will post 13.38 EPS for the current year.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.